全文获取类型
收费全文 | 3481篇 |
免费 | 176篇 |
国内免费 | 72篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 180篇 |
妇产科学 | 79篇 |
基础医学 | 383篇 |
口腔科学 | 71篇 |
临床医学 | 355篇 |
内科学 | 754篇 |
皮肤病学 | 123篇 |
神经病学 | 230篇 |
特种医学 | 346篇 |
外科学 | 313篇 |
综合类 | 39篇 |
预防医学 | 419篇 |
眼科学 | 33篇 |
药学 | 214篇 |
中国医学 | 4篇 |
肿瘤学 | 158篇 |
出版年
2023年 | 19篇 |
2022年 | 12篇 |
2021年 | 41篇 |
2020年 | 28篇 |
2019年 | 39篇 |
2018年 | 97篇 |
2017年 | 56篇 |
2016年 | 57篇 |
2015年 | 75篇 |
2014年 | 87篇 |
2013年 | 140篇 |
2012年 | 180篇 |
2011年 | 199篇 |
2010年 | 115篇 |
2009年 | 114篇 |
2008年 | 175篇 |
2007年 | 238篇 |
2006年 | 184篇 |
2005年 | 185篇 |
2004年 | 209篇 |
2003年 | 161篇 |
2002年 | 169篇 |
2001年 | 109篇 |
2000年 | 97篇 |
1999年 | 92篇 |
1998年 | 40篇 |
1997年 | 51篇 |
1996年 | 40篇 |
1995年 | 44篇 |
1994年 | 41篇 |
1993年 | 33篇 |
1992年 | 58篇 |
1991年 | 51篇 |
1990年 | 39篇 |
1989年 | 56篇 |
1988年 | 54篇 |
1987年 | 61篇 |
1986年 | 34篇 |
1985年 | 36篇 |
1984年 | 20篇 |
1983年 | 18篇 |
1982年 | 19篇 |
1980年 | 15篇 |
1979年 | 13篇 |
1978年 | 15篇 |
1977年 | 15篇 |
1975年 | 13篇 |
1974年 | 11篇 |
1973年 | 13篇 |
1972年 | 12篇 |
排序方式: 共有3729条查询结果,搜索用时 31 毫秒
1.
2.
Diane Purper-Ouakil Hilario Blasco-Fontecilla Tomas Ros Eric Acquaviva Tobias Banaschewski Sarah Baumeister Elisa Bousquet Aurore Bussalb Marie Delhaye Richard Delorme Renate Drechsler Allison Goujon Alexander Häge Anna Kaiser Louis Mayaud Konstantin Mechler Caroline Menache Olivier Revol Friederike Tagwerker Susanne Walitza Anna Maria Werling Stephanie Bioulac Daniel Brandeis 《Journal of child psychology and psychiatry, and allied disciplines》2022,63(2):187-198
3.
Dal Canto Elisa Remmelzwaal Sharon van Ballegooijen Adriana Johanne Handoko M. Louis Heymans Stephane van Empel Vanessa Paulus Walter J. Nijpels Giel Elders Petra Beulens Joline WJ 《Heart failure reviews》2022,27(1):207-218
Heart Failure Reviews - This study aimed to evaluate the diagnostic performance of echocardiographic markers of heart failure with preserved ejection fraction (HFpEF) and left ventricular diastolic... 相似文献
4.
Alina Vrieling H. Bas Bueno-De-Mesquita Martine M. Ros Ellen Kampman Katja K. Aben Frederike L. Büchner Eugène H. Jansen Nina Roswall Anne Tjønneland Marie-Christine Boutron-Ruault Claire Cadeau Jenny Chang-Claude Rudolf Kaaks Steffen Weikert Heiner Boeing Antonia Trichopoulou Pagona Lagiou Dimitrios Trichopoulos Sabina Sieri Domenico Palli Salvatore Panico Petra H. Peeters Elisabete Weiderpass Guri Skeie Paula Jakszyn María-Dolores Chirlaque Eva Ardanaz María-José Sánchez Roy Ehrnström Johan Malm Börje Ljungberg Kay-Tee Khaw Nick J. Wareham Paul Brennan Mattias Johansson Elio Riboli Lambertus A. Kiemeney 《International journal of cancer. Journal international du cancer》2019,145(9):2349-2359
Published associations between dietary folate and bladder cancer risk are inconsistent. Biomarkers may provide more accurate measures of nutrient status. This nested case–control analysis within the European Prospective Investigation into Cancer and Nutrition (EPIC) investigated associations between pre-diagnostic serum folate, homocysteine, vitamins B6 and B12 and the risk of urothelial cell carcinomas of the bladder (UCC). A total of 824 patients with newly diagnosed UCC were matched with 824 cohort members. Serum folate, homocysteine, and vitamins B6 and B12 were measured. Odds ratios (OR) and 95% confidence intervals (CI) for total, aggressive, and non-aggressive UCC were estimated using conditional logistic regression with adjustment for smoking status, smoking duration and intensity, and other potential confounders. Additionally, statistical interaction with smoking status was assessed. A halving in serum folate concentrations was moderately associated with risk of UCC (OR: 1.18; 95% CI: 0.98–1.43), in particular aggressive UCC (OR: 1.34; 95% CI: 1.02–1.75; p-heterogeneity = 0.19). Compared to never smokers in the highest quartile of folate concentrations, this association seemed only apparent among current smokers in the lowest quartile of folate concentrations (OR: 6.26; 95% CI: 3.62–10.81, p-interaction = 0.07). Dietary folate was not associated with aggressive UCC (OR: 1.26; 95% CI: 0.81–1.95; p-heterogeneity = 0.14). No association was observed between serum homocysteine, vitamins B6 and B12 and risk of UCC. This study suggests that lower serum folate concentrations are associated with increased UCC risk, in particular aggressive UCC. Residual confounding by smoking cannot be ruled out and these findings require confirmation in future studies with multiple measurements. 相似文献
5.
6.
Luciana Rodrigues da Cunha Diego Alves Vieira Yala Gramigna Giampietro Adriana Dias Gomes César Lúcio Lopes de Faria Jr Fabrício Freire de Melo Rosângela Teixeira Andrea Teixeira de Carvalho Luciana Maria Oliveira Olindo Assis Martins Filho Gifone Aguiar Rocha Dulciene Maria de Magalhães Queiroz Fernando Silva Neves Luciana Diniz Silva 《Clinics and research in hepatology and gastroenterology》2019,43(4):417-426
7.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献
8.
9.
Tom De Beule T Boulanger S Heye WJ van Rooij WH van Zwam L Stockx 《Interventional neuroradiology》2021,27(1):51
Background and purposeFlow diverters are increasingly used to treat intracranial aneurysms. We report the safety and efficacy of the p64 flow diverter, a resheathable and detachable device for intracranial aneurysms.Materials and methodsWe retrospectively reviewed 108 patients with 109 aneurysms treated with the p64 between March 2014 and July 2019. There were 87 women and 21 men, mean age 57 years. Of 109 aneurysms, 74 were discovered incidentally, 12 were symptomatic, 18 were previously treated, and five were ruptured dissection aneurysms. A total of 10 aneurysms were located in the posterior circulation. The mean aneurysm or remnant size was 8.1 mm.ResultsHemorrhage by perforation with the distal guidewire occurred in two patients with permanent neurological deficits in one. In one patient, acute in-stent occlusion caused infarction with a permanent deficit. Permanent morbidity was 1.9% (2 of 108, 95%CI 0.1–6.9%); there was no mortality. During follow-up, three in-stent occlusions occurred, all asymptomatic. There were no delayed hemorrhagic complications. At six months, 77 of 96 aneurysms (80.2%) were completely occluded, and at last follow-up, this increased to 93 of 96 aneurysms (96.9%). In-stent stenosis at any degree occurred in 11 patients, progressing to asymptomatic complete occlusion in one. In the other patients, stenosis resolved or improved at further follow-up.ConclusionThe p64 offers an effective and safe treatment option. Aneurysm occlusion rate was 97% at last follow-up, mostly achieved with a single device. There were no delayed hemorrhagic complications. Delayed in-stent stenosis infrequently progresses to occlusion but remains a matter of concern. 相似文献
10.
Karolina Pytka Neil Dawson Kyoko Tossell Mark A. Ungless Robin Plevin Ros R. Brett Trevor J. Bushell 《The European journal of neuroscience》2020,52(2):2838-2852
Mitogen‐activated protein kinases (MAPKs) regulate normal brain functioning, and their dysfunction is implicated in a number of brain disorders. Thus, there is great interest in understanding the signalling systems that control MAPK functioning. One family of proteins that contribute to this process, the mitogen‐activated protein kinase phosphatases (MKPs), directly inactivate MAPKs through dephosphorylation. Recent studies have identified novel functions of MKPs in foetal development, the immune system, cancer and synaptic plasticity and memory. In the present study, we performed an unbiased investigation using MKP‐2?/? mice to assess whether MKP‐2 plays a global role in modulating brain function. Local cerebral glucose utilization is significantly increased in the ventral tegmental area (VTA) of MKP‐2?/? mice, with connectivity analysis revealing alterations in VTA functional connectivity, including a significant reduction in connectivity to the nucleus accumbens and hippocampus. In addition, spontaneous excitatory postsynaptic current frequency, but not amplitude, onto putative dopamine neurons in the VTA is increased in MKP‐2?/? mice, which indicates that increased excitatory drive may account for the increased VTA glucose utilization. Consistent with modified VTA function and connectivity, in behavioural tests MKP‐2?/? mice exhibited increased sucrose preference and impaired amphetamine‐induced hyperlocomotion. Overall, these data reveal that MKP‐2 plays a role in modulating VTA function and that its dysfunction may contribute to brain disorders in which altered reward processing is present. 相似文献